PartnershipJun 22, 2026, 08:01 AM
LifeMD Partners with Halozyme for Exclusive XYOSTED Telehealth Program
AI Summary
LifeMD, Inc. announced a strategic co-marketing collaboration with Halozyme's wholly owned subsidiary, Antares Pharma, Inc. LifeMD will serve as the exclusive telehealth co-marketing partner for the XYOSTED self-pay program, an FDA-approved once-weekly subcutaneous testosterone auto-injector. The program, launching in July 2026 in 37 states, aims to expand access to hypogonadism treatment through virtual evaluations, preferred pharmacy dispensing, and consumer education, all for a transparent monthly price of approximately $249.
Key Highlights
- LifeMD formed an exclusive telehealth co-marketing partnership with Halozyme's Antares Pharma.
- The collaboration supports a direct-to-patient self-pay program for XYOSTED (testosterone enanthate) injection.
- XYOSTED is the only FDA-approved once-weekly subcutaneous testosterone auto-injector.
- LifeMD will provide virtual evaluations and its pharmacy will be the preferred dispensing pharmacy.
- The program launches in July 2026, initially available in 37 states.
- It offers an all-inclusive price of approximately $249 per month for medication and care.
- Companies will jointly invest in consumer education and promotional initiatives.
- XYOSTED was approved by the FDA in 2018.
Price Impact
More from LFMD